Clinical Trial Update: Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder [Phase 1]

View source ↗

Summary

An open-label Phase 1 study evaluated the pharmacokinetics of three subcutaneous extended-release olanzapine formulations in adults with schizophrenia or schizo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Olanzapine Extended-Release (SC) formulations (olanzapine)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D LLC | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 1 | Status: COMPLETED | Results posted: 2026-01-26